<DOC>
	<DOCNO>NCT00865228</DOCNO>
	<brief_summary>The purpose study determine role time dose lipid-lowering effect lapaquistat acetate , daily ( QD ) twice daily ( BID ) , subject hypercholesterolemia .</brief_summary>
	<brief_title>Efficacy Lapaquistat Acetate Subjects With Hypercholesterolemia</brief_title>
	<detailed_description>Dyslipidemias group metabolic disorder produce raised concentration lipoprotein , especially low-density lipoprotein cholesterol lipoprotein transport endogenous cholesterol liver peripheral tissue . Increased cholesterol triglyceride level lead increase risk arteriosclerosis , underlie cause heart attack , stroke peripheral vascular disease . Despite change lifestyle availability potent lipid-lowering agent , cardiovascular disease continue major cause death Western Europe North America . Lapaquistat acetate develop Takeda treatment hypercholesterolemia .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Females childbearing potential sexually active must agree use medically accept mean contraception , neither pregnant lactating Screening throughout duration study . Has prior Randomization mean lowdensity lipoprotein cholesterol great equal 130 mg/dL less equal 220 mg/dL 2 consecutive sample . Has prior Randomization mean triglyceride le 400 mg/dL 2 consecutive sample . Is willing able comply standardize , therapeutic lifestyle change diet equivalent . Has alanine aminotransferase aspartate aminotransferase level great 2 time upper limit normal screening period . Has serum creatinine great than133 mmol/L screen period . Has creatine phosphokinase great 3 time upper limit normal , identified screening period . Has active liver disease jaundice . Has history cancer remission le 5 year prior first dose study medication . Has endocrine disorder , Cushing syndrome , hyperthyroidism , inappropriately treated hypothyroidism , affect lipid metabolism . Has history myocardial infarction , angina pectoris , unstable angina , transient ischemic attack , cerebrovascular accident , peripheral vascular disease , abdomin al aorticaneurysm , coronary angioplasty , coronary peripheral arterial surgery multiple risk factor confer 10year risk cardiovascular disease great 20 % base Framingham risk scoring . Has positive hepatitis B surface antigen , antibody hepatitis C virus , determine medical history and/or subject 's verbal report . Has positive human immunodeficiency virus status take antiretroviral medication , determine medical history and/or subject 's verbal report . Has receive investigational compound within 30 day prior screen Visit 1 , currently participate another investigational study . Has receive lapaquistat acetate previous clinical study therapeutic agent . Has history presence clinically significant food allergy would prevent adherence specialize diet . Has know heterozygous homozygous familial hypercholesterolemia know type III hyperlipoproteinemia . Has fibromyalgia , myopathy , rhabdomyolysis , unexplained muscle pain . Has uncontrolled hypertension despite treatment Screening Visit 1 . Has inflammatory bowel malabsorption syndrome gastric bypass surgical procedure weight loss . Has history drug abuse alcohol abuse within past 2 year . Has stage I squamous cell carcinoma skin . Has type 1 type 2 diabetes mellitus . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Fluvastatin Lovastatin bile acid sequestrants ( eg , cholestyramine ) intestinal cholesterol uptake inhibitor ( eg , ezetimibe ) Fibrates ( eg , fenofibrate , gemfibrozil ) Niacin Cholestin red yeast rice fish oil plant sterols stanols orlistat sibutramine isotretinoin tacrolimus Probucol Systemic corticosteroid androgens Potent CYP3A4 inhibitor Cyclosporine Erythromycin Clarithromycin Telithromycin human immunodeficiency virus protease inhibitor amiodarone diltiazem verapamil nefazodone grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>